Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (577)	3/8/2005 2:20:54 AM
From: Icebrg	Read Replies (2) \| Respond to of 946

"Xyotax did for the most part what we thought it was going to do, except it fell short on the primary endpoint." James Bianco, March 2005.

To: Icebrg who wrote (577)	3/9/2005 6:15:57 PM
From: tuck	Read Replies (1) \| Respond to of 946

The patient populations being studied in the various Stellar trials are rather different. For example, there seems to be more variety in the Stellar 2 population than the Stellar 4: Stellar 2: cancer.gov Stellar 3: cancer.gov Stellar 4: cancer.gov 3 & 4 are the same. If the issue was poor data in historical survival data for PS 2 Stage IIIB/IV patients, that issue goes away to some extent in Stellar 2. Also in Stellar 4, since we're talking a different drug class. Maybe more hope for success than some think? Comments? Cheers, Tuck